General Biotechnology

If youve ever watched a patent case drag on for years, you already know the obvious ROI story: win in court, collect leverage, move on.
But theres a quieter, often undercounted ROI story that shows up in the backgroundespecially in method-of-use (MoU) …

Most pharma teams treat settlement like a win button. In court, that mindset is expensive.
Theres a familiar script in drug litigation: if the dispute is hard, settle. If the numbers look uncertain, settle. If the optics get messy, settle.
But drug…

Exelixis vs. Intas: When Generic Isnt a WordIts a Strategy
Theres a recurring misunderstanding in biotech: that generic competition is a straight linepatents fall, approvals follow, prices drop.
In reality, the biotech IP battleground is often a labyri…

Vertex vs. Squires: When IP Strategy Meets Access and Reality
Most legal battles in biotech are decided in the fine printclaims construction, prior art, expert declarations, and procedural timing. But every so often, a dispute spills beyond the court…

Short answer: Yesmost clinicians recommend checking liver‑function tests (LFTs) before starting simvastatin (Lipitor)… https://www.Drugchatter.com/chat/30440/is-liver-function-monitoring-necessary-with-lipitor/

Dish Technologies $DAZN Deal: What It Signals for the Future of Content, IP, and Corporate Strategy
In media and entertainment, the most expensive resource isnt bandwidthits rights. Rights to distribute, monetize, syndicate, localize, and protect intel…

What flexibility side effect are you referring to with Lipitor? Lipitor (atorvastatin) is known for specific… https://www.Drugchatter.com/chat/25856/can-lipitor’s-flexibility-side-effect-lead-to-long-term-issues/

Pharma IP teams didnt always have a dashboard for everything.
But the market has changed. The questions youre expected to answerfast, consistently, and with defensible evidencenow come from every direction: internal leadership, competitive intelligence…

A $50M generic R&D budget isnt a spendits a decision. And the decision starts with data.
In generic drugs, the line between launch-ready and stuck in litigation is often drawn long before any lab bench gets busy. The unglamorous truth? You dont jus…

Bio-betters are eating biosimilarsand the patent strategy game is changing.
The biosimilar wave was supposed to be the great democratizer of biologics: lower prices, faster competition, and a new era of access. But in the real worldwhere patents are li…